We are live on ! Find out more
BBC icon

Virtus Biotech Clinical Trials ETF
BBC

13 hedge funds and large institutions have $3.08M invested in Virtus Biotech Clinical Trials ETF in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more capital invested

Capital invested by funds: $2.81M → $3.08M (+$268K)

0.27% less ownership

Funds ownership: 27.81% → 27.55% (-0.27%)

7% less funds holding

Funds holding: 14 → 13 (-1)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
13
Holders Change
-1
Holders Change %
-7.14%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$347K
2
LPL Financial
LPL Financial
California
+$2.67K
3
VWM
Venturi Wealth Management
Texas
+$1.21K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$225K
2
Citadel Advisors
Citadel Advisors
Florida
-$151K
3
HI
Harbour Investments
Wisconsin
-$2.15K
4
GRP
Global Retirement Partners
California
-$1.11K
5
Comerica Bank
Comerica Bank
Texas
-$884
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$1.29M +$347K +12,565 +37%
Citadel Advisors
2
Citadel Advisors
Florida
$968K -$151K -5,469 -14%
Morgan Stanley
3
Morgan Stanley
New York
$368K -$225K -8,146 -38%
LPL Financial
4
LPL Financial
California
$358K +$2.67K +97 +0.8%
US Bancorp
5
US Bancorp
Minnesota
$27.9K – – –
FDCDDQ
6
Federation des caisses Desjardins du Quebec
Quebec, Canada
$23.4K – – –
DWS
7
Dynamic Wealth Strategies
California
$22K – – –
Osaic Holdings
8
Osaic Holdings
Arizona
$12.5K – – –
HI
9
Harbour Investments
Wisconsin
$6.48K -$2.15K -78 -25%
BWP
10
Baldwin Wealth Partners
Massachusetts
$2.79K – – –
VWM
11
Venturi Wealth Management
Texas
$1.23K +$1.21K +44 New
AF
12
Allworth Financial
California
$280 – – –
NA
13
NewEdge Advisors
Louisiana
$140 – – –
GRP
14
Global Retirement Partners
California
– -$1.11K -44 Closed
Comerica Bank
15
Comerica Bank
Texas
– -$884 -35 Closed

BBC Hedge Fund Activity: Q3 2024 in Review

13 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q3 2024, worth a combined $3.08M — up 9.5% from $2.81M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BBC and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.

The largest buyer was Susquehanna International Group, adding an estimated $347K. The largest seller was Morgan Stanley, cutting an estimated $225K.

  • 13 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q3 2024, down from 14 in Q2 2024.
  • Funds reported $3.08M of Virtus Biotech Clinical Trials ETF stock for Q3 2024, up 9.5% quarter-over-quarter.
  • 1 fund opened new Virtus Biotech Clinical Trials ETF positions in Q3 2024 and 2 closed out, a net change of -1 holder.
  • The largest Virtus Biotech Clinical Trials ETF buyer in Q3 2024 was Susquehanna International Group, an estimated $347K added.
  • The largest Virtus Biotech Clinical Trials ETF seller in Q3 2024 was Morgan Stanley, an estimated $225K sold.

Based on aggregated 13F filings for Q3 2024.